- Home
- HOPE vs SNDX Comparison
HOPE vs SNDX Comparison
Compare HOPE & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HOPE | SNDX |
|---|---|---|
| Founded | 1986 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2000 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HOPE | SNDX |
|---|---|---|
| Price | $14.45 | $19.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $14.50 | ★ $38.69 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.53% | N/A |
| EPS Growth | N/A | ★ 11.56 |
| EPS | ★ 0.49 | N/A |
| Revenue | N/A | ★ $172,352,000.00 |
| Revenue This Year | $42.00 | $107.19 |
| Revenue Next Year | $19.66 | $41.88 |
| P/E Ratio | $29.57 | ★ N/A |
| Revenue Growth | N/A | ★ 627.84 |
| 52 Week Low | $9.80 | $13.00 |
| 52 Week High | $14.50 | $25.59 |
Technical Indicators
Market Signals| Indicator | HOPE | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 64.05 | 42.55 |
| Support Level | $13.09 | $19.28 |
| Resistance Level | $14.48 | $22.40 |
| Average True Range (ATR) | 0.24 | 1.01 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 79.26 | 65.07 |
Price Performance
Historical ComparisonAbout HOPE Hope Bancorp Inc.
Hope Bancorp Inc is a bank holding company engaged in providing financial services. It offers core business banking products for small and medium-sized businesses and individuals. Services offered by the bank include online banking, mobile banking, mortgage loans, credit cards, investment and wealth management services, and other banking services.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.